Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186243 | 0.91 | PDE2A (0.43) | KCNH2SCN9ASCN5A | |
| SCHEMBL2186850 | 0.89 | ELANE (0.45) | — | |
| SCHEMBL2188289 | 0.85 | GLS (0.44) | GLSMAPK14ROCK2RIPK1ROCK1 | |
| SCHEMBL3529763 | 0.84 | SLC22A2 (0.43) | — | |
| SCHEMBL3524286 | 0.84 | ELANE (0.42) | — | |
| SCHEMBL2185146 | 0.84 | P2RX7 (0.47) | — | |
| SCHEMBL3523992 | 0.83 | SLC22A2 (0.47) | — | |
| SCHEMBL3528016 | 0.83 | ALDH1A1 (0.43) | — | |
| SCHEMBL2186951 | 0.82 | SLC22A2 (0.41) | — | |
| SCHEMBL2186891 | 0.82 | SLC22A2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1852434-B1 | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-7858788-B2 | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852434-A1 | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY | Shionogi Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | NR4A1, HAT1, NR4A2 | GLS 2393/4885KCNH2 3386/4885SCN9A 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.